Gala vs Pallas Health
Pallas Health's tirzepatide arrives as $897 every twelve weeks after a $179 opener; Gala's is a yearly rate for doses below the trial schedule.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Gala
Partner
$149/mo
Tirzepatide at $149 on a lower-dose protocol, billed against a yearly subscription. The dose is the thing to ask about before the price: a protocol pitched below the standard titration is a different product from the one the trials ran, whatever it costs.
- $149 is low for tirzepatide
- All fifty states
- The dose approach is stated rather than buried
- An app is included in the subscription
- A yearly term, not a rolling month
- A reduced-dose protocol is not what the trials tested
- The semaglutide figure on the site is not a monthly rate
- Compounding pharmacy is not named
Pick it for: A low-dose year you have chosen deliberately
Not for: Anyone who wants the standard titration, or a month-to-month arrangement.
Pallas Health
Partner
$325/mo
$199 and $299, flat as doses rise, across fifty-one states. A clean 50% step between the molecules.
- Provider care and check-ins included rather than billed on top
- Flat at every dose on both molecules
- The quarterly figure is published, so the average can be checked
- 51 jurisdictions
- The advertised monthly figure is never actually charged
- $597 lands as one charge, not three
- A reduced first month makes the early bill unrepresentative
- Injection only
Pick it for: Quarterly cash, and a rate that holds as doses rise
Not for: Anyone budgeting month to month, where the cycle matters more than the average.
Our verdict
Pallas advertises $299 a month for tirzepatide, which is $897 divided by three — and twelve weeks is 2.76 calendar months, not three, so the real rate is higher and the cash has to be there quarterly. Gala's figure is steady; the dose behind it is not. Gala states plainly that its protocol sits below the standard escalation, which is a different regimen from the one the tirzepatide trials ran — ask what milligram a year at $149 buys.
What actually separates them
Gala and Pallas Health state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Pallas Health costs $176 more than Gala — 118% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,788 at Gala against $3,900 at Pallas Health — a difference of $2,112.
| Gala | Pallas Health | |
|---|---|---|
| Published price | $149/mo | $325/mo |
| Where you can use it | 50 states | 51 jurisdictions |
Before you choose either
Coverage is not the same, and it decides the question outright for anyone living in the gap. Pallas Health serves 1 that Gala does not — DC. Check your own state before you weigh anything else here.
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.